New Drug Approvals

Home » Uncategorized » Tedatioxetine Revisited

Tedatioxetine Revisited

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

PAYPAL DONATIONS

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Blog Stats

  • 1,308,336 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,781 other followers

add to any

Share

Tedatioxetine.svg

Tedatioxetine

TEDATIOXETINE; UNII-5H681S8O3S; Lu AA24530; 508233-95-2;
Molecular Formula: C18H21NS
Molecular Weight: 283.43104 g/mol
4-{2-[(4-Méthylphényl)sulfanyl]phényl}pipéridine
508233-95-2 [RN]
Lu AA24530
Piperidine, 4-[2-[(4-methylphenyl)thio]phenyl]
  • OriginatorLundbeck A/S
  • DeveloperLundbeck A/S; Takeda
  • ClassAntidepressants; Anxiolytics; Piperidines
  • Mechanism of ActionBiogenic monoamine uptake inhibitors; Serotonin 2C receptor antagonists; Serotonin 3 receptor antagonists
  • Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 10 May 2016Discontinued – Phase-I for Generalised anxiety disorder in USA, Japan (PO)
  • 10 May 2016Discontinued – Phase-I for Major depressive disorder in USA, Japan (PO)
  • 30 Jul 2015Tedatioxetine is still in phase I trials for Major depressive disorders and Generalised anxiety disorder in USA and Japan

Tedatioxetine (Lu AA24530) is an antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takedaentered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate,vortioxetine.[1]

Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.[2][3][4][5]

As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck’s product pipeline.[6][7]

On May 10, 2016, all work on tedatioxetine stopped.[8]

PATENT

WO 2016151328

PATENT

WO 2015090160

Tedatioxetine chemical name 4- (2- (4-methylphenyl group)) phenylpiperidine by Lundbeck developed for the treatment of severe depression, it is a monoamine reuptake inhibitor, a monoamine reuptake transporter inhibitors, 5-HT3 antagonists and 5-HT2c receptor antagonist. For the treatment of major depressive disorder and generalized anxiety, II clinical study in. Tedatioxetine has the following structure:
According to the literature, the current synthesis routes are the following:
WO 2003/029232 discloses Tedatioxetine first preparation method, as shown in the following Scheme,
The method of low yield, the product is not easy purification by column chromatography requires; more important is the preparation of the compound N-Boc- piperidin-4-ol of the need to use butyl lithium, and reaction was carried out at lower temperatures, not conducive to industrial production.
WO 2009109541 provides a, as shown in the above-described method for improved routes following synthetic route,
Bn- replaced with Boc-, dehydroxylation switch to TFA and Et 3 of SiH, yield improved despite increased. But there are many shortcomings.Deficiencies mainly reflected in the following aspects: the compound used in the expensive starting 2-bromo benzene iodine source and a catalyst of palladium and a bidentate phosphine ligand 3, an increase of production cost; preparation of compound needed 4:00 butyl lithium reagent to the more dangerous, the need at a low temperature reaction. This will bring in the production of a big security risk, is not conducive to the operation; when dehydroxylation
Preparation of 2- (4-methyl-phenyl mercapto) phenylpiperidine hydrobromide, to use a lot of trifluoroacetate (15eq), post-processing is too much trouble and the environment have a greater pollution.
Given 4- [2- (4-methylphenyl) phenyl] piperidine and salts thereof possess excellent pharmacological properties, and deficiencies of the prior processes, is necessary to develop a suitable industrial production, easy to operate and environmentally friendly preparation process.

2- (4-methyl-phenylthio) benzaldehyde prepared as in Example 1
Direction of Na 2 CO. 3 stirred mixture (11g, 105mmol) and 30mlDMF added 4-methyl-thiophenol (12.4g, 100mmol), stirred for 20 minutes. To the mixture was slowly added 2-bromobenzaldehyde (18.4g, 100mmol); a pending completion of the addition, under nitrogen, was heated to 100 deg.] C for 6 hours. After completion of the reaction, the reaction solution was cooled to room temperature, 100ml of water was added and stirred for 30 minutes. Filtered, washed with water (30ml) and dried in vacuo to give the filter cake was washed with 20.5g pale green solid; After n-hexane to give 18.5g pale yellow solid was recrystallized from 2- (4-phenylthio) benzaldehyde (mp: 52- 54 ℃), 81% yield. 2- (4-methyl-phenylthio) benzaldehyde Example 2 Preparation of
To the K 2 CO. 3 stirred mixture (15g, 110mmol) and 30mlDMA added 4-methyl-thiophenol (12.6g, 102mmol), stirred for 20 minutes. To the mixture was slowly added 2-chlorobenzaldehyde (14g, 100mmol); a pending completion of the addition, under nitrogen, the reaction was heated to 100 deg.] C for 7 hours. After completion of the reaction, the reaction solution was cooled to room temperature, 100ml of water was added and stirred for 30 minutes. Filtered, washed with water (30ml) and dried in vacuo to give the filter cake was washed with 19.7g pale green solid; After n-hexane to give 17g as a pale yellow solid was recrystallized from 2- (4-phenylthio) benzaldehyde (melting point: 51-53 ℃), a yield of 77.5%
2- (4-methyl-phenylthio) benzaldehyde Example 3 Preparation of
Ask NaOH (4.2g, 105mmol) and stirred 50ml 1,4-dioxane was added 4-methyl-thiophenol (12.4g, 100mmol), stirred for 30 minutes. To the mixture was slowly added 2-iodo-benzaldehyde (23.1g, 100mmol); a pending completion of the addition, under nitrogen, was heated under reflux for 5 hours.After completion of the reaction, the reaction solution was cooled to room temperature, 50ml of water was added, extraction separated; the organic phase was washed with 50ml of ethyl acetate, and the combined organic phases were washed with 20% aqueous ammonium chloride solution and saturated brine, dried over anhydrous magnesium sulfate, filtration and concentration gave 21g viscous liquid, and cooled to solidify; after n-hexane to give 18.1g pale yellow solid was recrystallized from 2- (4-phenylthio) benzaldehyde (m.p.: 53-54 ℃), close rate of 79%.
Example 4 Preparation of 3- [2 (4-methyl) phenyl] pentanedioic acid
1) Preparation of ethyl-2-cyano-3- (2- (4-methyl) phenyl) acrylate
2- (4-methylphenyl thio) benzaldehyde (4g, 17.5mmol), ethyl cyanoacetate (2.4g 21mmol) and toluene (30ml) was added a mixture of glacial acetic acid (5ml) and piperidine (0.3 ml of) stirred for 10 minutes; heated to reflux, and isolating the resulting water trap. Completion of the reaction, cooled to room temperature; the reaction was washed with 30ml water and 30ml saturated sodium bicarbonate solution, dried over anhydrous magnesium sulfate; filtered, and concentrated to give 5.0g yellow liquid (solidifies on cooling), yield 86%. It was used directly in the next reaction without purification.
2) Preparation of Diethyl 2,4-diethyl-3- (2- (4-methyl) phenyl) glutarate
Sodium methoxide (1.9g, 35mmol) and dry THF (30ml) was stirred and cooled to mix 0-5 ℃, was added dropwise diethyl malonate (4.6g, 35mmol), stirred for 15 minutes at room temperature dropwise Bi; dropwise obtained above in step 2-cyano-3- (2- (4-methyl) phenyl) acrylate (5g, 15.4mmol) and dry tetrahydrofuran (40ml) solution; BI dropwise, at room temperature stirred for 13 hours. Completion of the reaction, the reaction mixture was added 150ml20% aqueous ammonium chloride solution, followed by extraction separated; the aqueous phase was extracted with ethyl acetate, the combined organic phase was dried over anhydrous magnesium sulfate; filtered, and concentrated to give 5.4 g of a viscous liquid, yield 78%. It was used directly in the next reaction without purification.
Was added 6N hydrochloric acid (70ml), was heated at reflux for 3 days the material obtained in the above step (5.4 g of); completion of the reaction, slowly cooled to room temperature, added 50ml of ethyl acetate, stirred for 30 minutes to precipitate a solid from the solution, filtered and washed with 20ml washed with ethyl acetate, and dried in vacuo at 50 ℃ 10 hours to give 2.7g of white solid 3- [2 (4-methylphenyl) phenyl] glutaric acid (melting point: 191-195 ℃), in 58% yield.
Example 5 Preparation of 3- [2- (4-phenylthio) phenyl] pentanedioic acid
To ethyl acetoacetate (13g, 100mmol) and piperidine (1.7g, 10mmol) was added a mixture of 2- (4-methyl-phenylthio) benzaldehyde (11.5g, 50mmol), room temperature for 1 day to give a yellow viscous semi-solid, 2.7g of sodium methoxide was added. after stirring for 1 hour cure, stand for 2 days.To the above mixture was added ethanol (180ml) and 40% aqueous sodium hydroxide (140ml) was stirred and heated to reflux for 4-5 hours the reaction. Completion of the reaction the heating was stopped, and after cooling to room temperature, the solvent was distilled off under reduced pressure; the residue after distillation under cooling in an ice water bath, and treated dropwise with concentrated hydrochloric acid (150ml) adjusted to pH 1-2. 300ml ethyl acetate was added, the aqueous phase was extracted with 300ml of ethyl acetate, and the combined organic phases were washed with 300ml water; the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to 500ml of the solvent. The residue was cooled to room temperature, stirred for 2 hours. The title compound was isolated by filtration through with ethyl acetate (20ml) and was washed and dried at 50 deg.] C in vacuo overnight to give 21.5g of white solid 3- [2 (4-methylphenyl) phenyl] glutaric acid (melting point: 194-196 ℃) yield 65%.
1HNMR(DMSO‐d6):δ2.28(S,3H),2.54‐2.65(m,4H),4.09‐4.16(m,1H),7.08‐7.17(m,4H),7.21‐7.26(m,3H),7.39(d,J=8.1Hz,1H),12.15(s,2H).ESI‐MS(m/z):353.10[M+Na]+.
Example 6 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-dione
Mixing the compound 3- [2 (4-methyl) phenyl] glutaric acid (10g, 30mmol) and urea (5.4g, 90mmol) prepared in Step stirred and heated to 146 deg.] C for 4 hours ; after completion of the reaction was monitored by TLC, cooled to 80 deg.] C, was slowly added 70ml of water and 70ml of ethanol was stirred for 30 minutes; cooled to room temperature and stirred for 1 hour. The title compound was filtered absolute ethanol (170ml) and recrystallized from 50 deg.] C overnight and dried in vacuo to give 8.0g white solid 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-di -one (mp: 164-166 ℃), yield 86%
1HNMR(CDCl3):δ2.33(S,3H),2..86(dd,J=17.2,4.4Hz,2H),2.69‐2.76 (m,2H),3.99‐4.08(m,1H),7.10‐7.15(m,4H),7.18‐7.30(m,4H),8.78(brs,1H).ESI‐MS(m/z):312.1[M+H]+.
7 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-dione Example
In four of 250ml equipped with a condenser reaction flask was added 3- [2 (4-methyl) phenyl] glutaric acid (10g, 30mmol) and urea (14.4g, 240mmol) and the mixture was stirred and heated to 146 deg.] C for 4 hours; TLC monitoring completion of the reaction, cooled to 100 deg.] C, was slowly added 70ml of water and 70ml of ethanol was stirred for 30 minutes; cooled to room temperature and stirred for 1 hour. The title compound was filtered absolute ethanol (170ml) and recrystallized from 50 deg.] C overnight and dried in vacuo to give 7.8g white solid 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-di -one (mp: 165-166 ℃), yield 84%.
8 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-dione Example
In four of 250ml equipped with a condenser reaction flask was added 3- [2 (4-methyl) phenyl] pentanedioic acid (5g, 15mmol) and urea (1.8g, 30mmol) and the mixture was stirred and heated to 143 deg.] C for 4 hours; cool to 100 deg.] C, was slowly added 35ml of water and 35ml of ethanol was stirred for 30 minutes; cooled to room temperature and stirred for 1 hour. The title compound was filtered absolute ethanol (70ml) and recrystallized from 50 deg.] C overnight and dried in vacuo to give an off-white solid 2.9g of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-dione (Melting point: 163-166 ℃), a yield of 63%.
9 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-dione Example
The compound prepared in the step of 3- [2 (4-methyl) phenyl] glutaric acid (10g, 30mmol) and urea (3.6g, 60mmol) were mixed and stirred and heated to 146 deg.] C for 4 hours ; after completion of the reaction was monitored by TLC, cooled to 80 deg.] C, was slowly added 70ml of water and 70ml of ethanol was stirred for 30 minutes; cooled to room temperature and stirred for 1 hour. The title compound was filtered, absolute ethanol (45 ml of) and recrystallized from 50 deg.] C overnight and dried in vacuo to give 8.0g white solid 4- [2- (4-methylphenyl) phenyl] piperidine-2,6 dione (melting point: 164-166 ℃), yield 86%.
10 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6-dione Example
A step of preparing the compound 3- [2 (4-methylphenyl) phenyl] glutaric acid (19.8g, 60mmol) and urea (21.6g, 360mmol) were mixed and stirred and heated to 144 deg.] C for 4 hours; after completion of the reaction was monitored by TLC, cooled to 100 deg.] C, slowly added water 140ml 140ml ethanol and stirred for 30 min; cooled to room temperature and stirred for 1 hour. The title compound was filtered, absolute ethanol (350ml) and recrystallized from 50 deg.] C overnight and dried in vacuo to give a white solid 16.5g of 4- [2- (4-methylphenyl) phenyl] piperidine-2,6 dione (melting point: 164-166 ℃), yield 88%.
Example 11 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine
Tetrahydro lithium aluminum (5.1g, 39mmol) with 140ml of tetrahydrofuran were mixed and stirred ice bath cooled to 8 ℃, under nitrogen, was added dropwise 4- (2-mercapto-methylphenyl) piperidine-2,6-phenyl one (7g) in tetrahydrofuran (140ml) solution, so that the temperature does not exceed 20 ℃; dropping was completed, the reaction at room temperature for 5 hours. The reaction solution was cooled in an ice-water bath, was slowly added dropwise 30ml of water, stirred for 20 minutes. The reaction mixture was added sodium sulfate (20g), stirred for 30 minutes. Filtered and the filtrate was concentrated to give a colorless liquid (4.5g), cooled to solidify to a white solid of 4- [2- (4-methylphenyl) phenyl] piperidine.
Example 12 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine
The reaction flask was added 100ml four 1mol / l borane tetrahydrofuran solution (40ml, 40mmol), cooled to ice bath 5 ℃; under nitrogen was added dropwise 4- (2-mercapto-methylphenyl) piperidine-2-phenyl , 6-dione (3.1g) in tetrahydrofuran (40ml) solution, so that the temperature does not exceed 10 ℃; dropping was completed, the reaction at room temperature for 20 hours. The reaction solution was cooled to 0 deg.] C, and slowly added dropwise 1mol / l HCl (30mL), dropwise finished warming at reflux for 5 hours; of THF was removed and concentrated, 30ml of ethyl acetate and washed with an aqueous solution, a saturated aqueous sodium bicarbonate was added to adjust the pH> 10 , followed by addition of 50ml of ethyl acetate, the organic phase was dried, filtered and concentrated to give 1.8g of a colorless liquid, and cooled to solidify to a white solid of 4- [2- (4-methyl) phenyl] piperidine.
Example 13 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine
The a 2 mol / L the BH 3 .CH 3 the SCH 3 (20 mL) and diethylene glycol dimethyl ether 20ml were mixed and stirred ice bath cooled to 10 ℃, solution of 4- (2-mercapto-methyl-phenyl) phenylpiperidine pyridine 2,6-dione (3.1g) in diethylene glycol dimethyl ether (60ml) solution, so that the temperature does not exceed 20 ℃; dropping was completed, the reaction at room temperature 0.5 hours, then slowly heated to 120 deg.] C for 10 hours. The reaction solution was cooled to 0 deg.] C, and slowly added dropwise 30ml of methanol, a dropping was completed, the mixture was stirred overnight at room temperature; was added 4mol / l HCl / EA (10ml ), was heated to 100 deg.] C for 4 hours; the resulting residue was distilled under reduced pressure was dissolved in 30ml water, saturated aqueous sodium bicarbonate was added to adjust the pH> 10, followed by addition of 50ml of ethyl acetate, the organic phase was dried, filtered and concentrated to give a pale red liquid; after column chromatography (hexane – acetic acid – ethanol 10 : 1.5: 0.5) to give a white solid (0.9g) 4- [2- (4- methylphenylsulfanyl) phenyl] piperidine after purification.
14 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine hydrochloride Example
The step resulting 4- [2- (4-methylphenyl) phenyl] piperidine (4g, 14mmol) was added to absolute ethanol (30ml) and heated to 50 deg.] C to dissolve; 4mol slowly added dropwise / l hydrogen chloride – ethyl acetate solution (4ml), 40 minutes with the reaction temperature; cooled to 5-10 ℃ stirred for 2 hours, filtered through a cake when the ethanol (5ml) and washed with 44 ℃ overnight and dried in vacuo to give 3.2 g of white solid 4- [2- (4-methylphenyl) phenyl] piperidine hydrochloride (melting point: 222-225 ℃), 75% yield.
15 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine hydrochloride Example
4- [2- (4-methylphenyl) phenyl] piperidine (4g, 14mmol) was added to acetone (20ml) and heated to 50 deg.] C to dissolve; 37% was gradually added dropwise concentrated hydrochloric acid ( 1.5ml), 40 minutes with the reaction temperature; cooled with stirring to 5-10 ℃ 2 hours, filtered through a cake of acetone (5ml) and washed with 44 ℃ vacuum dried overnight to give 3.6g of white solid 4- [2- ( 4-methylphenyl) phenyl] piperidine hydrochloride (melting point: 224-227 ℃), in 80% yield.
Example 16 Preparation of 4- [2- (4-methylphenyl) phenyl] piperidine hydrochloride embodiment
Tetrahydro Lithium aluminum (19g, 500mmol) and 200ml of tetrahydrofuran were mixed and stirred at room temperature was added dropwise 4- (2-mercapto-methylphenyl) piperidine-2,6-dione phenyl (31.1g, 100mmol) and tetrahydrofuran ( 200ml) solution, the temperature does not exceed 35 ℃; dropping was completed, the reaction heated under reflux for 3 hours. The reaction solution was cooled in an ice-water bath, was slowly added dropwise 100ml of saturated aqueous sodium sulfate solution, stirred for 60 minutes. The reaction mixture was added ethyl acetate (200ml) and anhydrous magnesium sulphate (50g) was stirred for 60 minutes. Filtered and the filtrate was concentrated to give a colorless liquid. Was added to 80ml of acetone and heated to 40 ℃ dissolved, was added quickly 4mol / l hydrogen chloride – ethyl acetate solution (10ml), seeded, stirred for 20 minutes to precipitate a white solid. 40 ℃, slowly dropping the remaining hydrogen chloride – ethyl acetate solution (20ml). Drop Bi, 5-10 ℃ for 3 hours. The filtered cake in acetone (30ml) and washed with 44 ℃ when dried in vacuo overnight to give 20.8g of white solid 4- [2- (4-methylphenyl) phenyl] piperidine hydrochloride (melting point: 225-228 ℃), yield 66%.
TLC:Rf 0.15(chloroform:methanol=9:1);1HNMR(CDCl3):δ6.83(d,J=8.1Hz,1H),6.74(d,J=1.9Hz,1H),6.68(dd,J=8.1,1.9Hz,1H),4.75(m,1H),3.68(s,3H),3.36(m,1H),3.31(br,2H),3.02‐2.94(m,2H),2.58‐2.52(m,2H),1.94‐1.39(m,12H).

References

External links

Patent ID Date Patent Title
US2010144788 2010-06-10 4- [2- (4-METHYLPHENYLSULFANYD-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION
US2010137366 2010-06-03 4- [2- (4-METHYLPHENYLSULFANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS)
US2010105730 2010-04-29 LIQUID FORMULATIONS OF SALTS OF 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE
US7683053 2010-03-23 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS
US2009264465 2009-10-22 CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN
US7148238 2006-12-12 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
US7144884 2006-12-05 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
US7138407 2006-11-21 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Patent ID Date Patent Title
US2015073018 2015-03-12 CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE
US8920840 2014-12-30 Enteric tablet
US2014296290 2014-10-02 THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER
US2014163043 2014-06-12 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS
US2013190352 2013-07-25 CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN
US8476279 2013-07-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
US8110567 2012-02-07 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS
US2011053978 2011-03-03 THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER
US2011054178 2011-03-03 PROCESS FOR THE MANUFACTURE OF [PHENYLSULFANYLPHENYL]PIPERIDINES
US2011039890 2011-02-17 4-[2, 3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
Tedatioxetine
Tedatioxetine.svg
Tedatioxetine ball-and-stick model.png
Systematic (IUPAC) name
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 508233-95-2 Yes
ATC code none
PubChem CID 9878913
ChemSpider 8054590 Yes
KEGG D10170 
Synonyms Lu AA24530; Lu-AA-24530
Chemical data
Formula C18H21NS
Molar mass 283.43 g/mol

//////////////tedatioxetine, WO 2016151328, Lu AA24530, 508233-95-2

CC1=CC=C(C=C1)SC2=CC=CC=C2C3CCNCC3


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Paypal Donate

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,781 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: